首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1419133

特发性肺纤维化治疗市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按药物类型、配销通路和地理位置

Idiopathic Pulmonary Fibrosis Treatment Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Type, Distribution Channel, and Geography

出版日期: 2023年12月12日 | 出版商:

The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格

简介目录

全球特发性肺纤维化治疗市场规模预计将从2022年的43.6亿美元激增至2030年的107.84亿美元；预计 2022 年至 2030 年该市场将以 12.0% 的CAGR成长。

吸烟人数的增加推动了特发性肺纤维化治疗市场的成长

吸烟是发生特发性肺纤维化的众所周知的危险因子之一。最近的研究表明，吸烟可能对特发性肺纤维化治疗患者的生存产生不利影响。几项研究提供的证据表明，氧化压力增加可能会促进目前和先前吸烟者的特发性肺纤维化患者的疾病进展。

香烟烟雾中含有粒状物、剧毒活性氧和活性氮（RONS）以及其他化学物质。这些成分会引发体内肿胀，导致各种疾病，包括肺纤维化和癌症。根据美国疾病管制与预防中心(CDC) 2023 年5 月发布的最新数据，美国18 岁及以上成年人中，每100 名成年人中约有12 名（约占人口的11.5%）吸烟，美国成年吸烟者总数为2,830 万人。因此，吸烟人数的激增预计将推动特发性肺纤维化治疗市场的成长。

特发性肺纤维化负担的增加推动了特发性肺纤维化治疗市场的成长

根据美国肺臟协会 2022 年 11 月更新的资料，美国每年诊断出约 5 万例新发特发性肺纤维化病例。这种情况的症状在 50-70 岁的患者身上更为明显。根据 2022 年 9 月发表在《英国医学杂誌》上的一篇文章，预计 2021 年专科护理病房中特发性肺纤维化的盛行率为每 10 万人中 36.0 人。由于老化、肥胖、高血压或家族史等常见危险因素，全世界患有特发性肺纤维化的患者数量不断增加，且该疾病正在成为经济体的重大社会经济负担。因此，特发性肺纤维化患者数量的增加推动了纤维化疾病治疗市场的成长。

基于药物类型的见解

依药物类型，特发性肺纤维化治疗市场分为尼达尼布、吡非尼酮等。尼达尼布细分市场在 2022 年占据更大的市场份额。预计其他细分市场在 2022 年至 2030 年期间的CAGR将达到 46.3%。吡非尼酮和尼达尼布是治疗纤维化疾病的常用药物。

基于配销通路的见解

依配销通路，全球特发性肺纤维化治疗市场分为医院药房、零售药房和网路药房。医院药局细分市场在 2022 年占据最大市场份额。线上药局细分市场预计 2022 年至 2030 年CAGR最高，达到 17.4%。

领先企业正在实施策略，例如扩大市场份额和多元化、推出新产品以及获取新客户群，以挖掘现有商机。

2023 年5 月，Cumberland Pharmaceuticals Inc. 宣布其II 期临床试验的研究性新药申请(IND) 获得FDA 批准，该试验重点关注患有特发性肺纤维化的患者，特发性肺纤维化是进行性纤维化肺部疾病的主要形式。这项批准代表了特发性肺纤维化潜在治疗方法向前迈出的关键一步，并给受这种挑战性疾病影响的人们带来了希望。

2022 年10 月，勃林格殷格翰在评估BI 1015550 的FIBRONEER-IPF III 期研究中招募了第一位美国患者。BI 1015550 是一种实验性磷酸二酯酶4B (PDE4B) 抑制剂，被发现用于治疗患有特发性肺纤维化的个体。该研究是全球FIBRONEER 计划的一部分，该计划包括两项III 期研究：针对特发性肺纤维化患者的FIBRONEER-IPF 和针对患有其他进行性纤维化间质性肺疾病(ILD) 的成人患者的FIBRONEER-ILD。

2022 年 6 月，Accord Healthcare, Inc. 宣布将吡非尼酮加入其固体口服产品组合。这种新药被批准用于治疗特发性肺纤维化，因为它的治疗效果与基因泰克公司的 Esbriet 相当。

2022年5月，山德士推出了仿製药吡非尼酮，这是第一个AB级（完全可替代）的仿製药，相当于基因泰克的Esbriet，用于治疗特发性肺纤维化患者。这种口服药物透过专科药房以 0 美元共付额计划向符合条件的患者提供。

2022年3月，领先的製药公司百时美施贵宝宣布透过最终合併协议以每股76.00美元收购Turning Point Therapeutics, Inc.。此次收购显着增强了百时美施贵宝在製药市场的全球影响力，使其能够更加积极主动地为产业带来创新，同时扩大其挽救生命的疗法和治疗组合。

2021年6月，罗氏集团成员基因泰克向美国食品药物管理局（FDA）提交补充新药申请（sNDA）后，Esbriet（吡非尼酮）获得优先审查

美国食品药物管理局、疾病管制与预防中心 (CDC) 和全球疾病负担研究是准备特发性肺纤维化治疗市场报告时参考的主要和次要来源。

欧洲
- 德国
- 法国
- 义大利
- 西班牙
- 英国
- 欧洲其他地区
亚太
- 澳洲
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区
南美洲和中美洲
- 巴西
- 阿根廷
- 南美洲和中美洲其他地区

第 10 章：产业格局

併购
协议、合作、合资企业
新产品发布
扩张和其他策略发展

第 11 章：竞争格局

关键参与者的热图分析
公司定位与专注

第 12 章：特发性肺纤维化治疗市场 - 主要公司概况

F. Hoffmann-La Roche Ltd

注意 - 将为以下公司列表提供类似信息

勃林格殷格翰
阿斯利康
百时美施贵宝
盐野义株式会社
西普拉有限公司
其他的

第 13 章：附录

词彙表
关于 Insight Partners
市场情报云

简介目录

Product Code: TIPRE00005557

The global idiopathic pulmonary fibrosis treatment market size is projected to surge from US$ 4.360 billion in 2022 to US$ 10.784 billion by 2030; the market is estimated to grow at a CAGR of 12.0% during 2022-2030.

Increasing Number of People Smoking Cigarettes Fuels Idiopathic Pulmonary Fibrosis Treatment Market Growth

Cigarette smoking is one of the well-known risk factors for the development of idiopathic pulmonary fibrosis. Recent studies suggest that smoking may have a detrimental effect on the survival of patients with idiopathic pulmonary fibrosis treatment. Several studies have produced evidence suggesting that increased oxidative stress may promote disease progression in idiopathic pulmonary fibrosis patients who are current and former smokers.

Cigarette smoke contains particulate matter, highly toxic reactive oxygen and nitrogen species (RONS), and other chemicals. These constituents trigger swelling in the body and thus lead to various diseases, including pulmonary fibrosis and cancer. According to the Centers for Disease Control and Prevention (CDC) updates released in May 2023, approximately 12 out of 100 adults (~11.5% of the population) aged 18 and older in the US smoke cigarettes, totaling 28.3 million adult smokers in the US. Therefore, an upsurge in the number of people smoking cigarettes is expected to drive the growth of the idiopathic pulmonary fibrosis treatment market.

Growing Burden of Idiopathic Pulmonary Fibrosis Fuels Idiopathic Pulmonary Fibrosis Treatment Market Growth

According to data from the American Lung Association, updated in November 2022, approximately 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed in the US each year. Symptoms of this condition are more noticeable in patients of age 50-70. According to an article published in the British Medical Journal in September 2022, the estimated prevalence of idiopathic pulmonary fibrosis in specialized care units in 2021 was 36.0 per 100,000. The number of patients suffering from idiopathic pulmonary fibrosis is increasing worldwide due to common risk factors such as aging, obesity, high blood pressure (hypertension), or family history, and the condition is becoming a significant socioeconomic burden for economies. Therefore, the increasing number of patients with idiopathic pulmonary fibrosis propels bolsters the fibrotic disease treatment market growth.

Drug Type -Based Insights

Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022-2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.

Distribution Channel -Based Insights

By distribution channel, the global idiopathic pulmonary fibrosis treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The online pharmacies segment is anticipated to register the highest CAGR of 17.4% during 2022-2030.

Leading players are implementing strategies such as expansion and diversification of their market presence, launch of new products, and acquisition of a new customer base for tapping prevailing business opportunities.

In May 2023, Cumberland Pharmaceuticals Inc. announced receiving FDA approval for its Investigational New Drug Application (IND) for a Phase II clinical trial focused on patients suffering from idiopathic pulmonary fibrosis, the predominant form of progressive fibrosing lung disease. This approval represents a critical step forward in the advancement of potential treatments for idiopathic pulmonary fibrosis and gives hope to those affected by this challenging disease.

In October 2022, Boehringer Ingelheim enrolled the first US patient in the FIBRONEER-IPF Phase III study evaluating BI 1015550. BI 1015550 is an experimental phosphodiesterase 4B (PDE4B) inhibitor discovered for treating individuals suffering from idiopathic pulmonary fibrosis. The study is a part of the global FIBRONEER program, which includes two Phase III studies: FIBRONEER-IPF in patients with idiopathic pulmonary fibrosis and FIBRONEER-ILD in adults with other progressive fibrosing interstitial lung diseases (ILDs).

In June 2022, Accord Healthcare, Inc. announced the addition of pirfenidone to its solid oral product portfolio. This new drug is approved for the treatment of idiopathic pulmonary fibrosis, as it is therapeutically equivalent to Genentech's Esbriet.

In May 2022, Sandoz launched its generic pirfenidone, the first AB-rated (fully substitutable) equivalent to Genentech's Esbriet, for the treatment of patients with idiopathic pulmonary fibrosis. This oral medication was made available for eligible patients through specialty pharmacies with a $0 copay program.

In March 2022, Bristol Myers Squibb, a leading pharmaceutical company, announced the acquisition of Turning Point Therapeutics, Inc. for US$ 76.00 per share through a definitive merger agreement. This acquisition has significantly strengthened Bristol Myers Squibb's global presence in the pharmaceutical market, allowing it to be more proactive in bringing innovations to the industry while expanding its portfolio of life-saving therapies and treatments.

In June 2021, Genentech, a member of the Roche Group, was granted a priority review FOR Esbriet (pirfenidone) after it submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA)

The US Food and Drug Administration, Centers for Disease Control and Prevention (CDC), and Global Burden of Disease Study are among the primary and secondary sources referred to while preparing the idiopathic pulmonary fibrosis treatment market report.

1. Introduction

1.1 Scope of the Study
1.2 Market Definition, Assumptions and Limitations
1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Market Attractiveness Analysis

3. Research Methodology

4. Idiopathic Pulmonary Fibrosis Treatment Market Landscape

4.1 Overview
4.2 PEST Analysis
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain

5. Idiopathic Pulmonary Fibrosis Treatment Market - Key Market Dynamics

5.1 Key Market Drivers
5.2 Key Market Restraints
5.3 Key Market Opportunities
5.4 Future Trends
5.5 Impact Analysis of Drivers and Restraints

6. Idiopathic Pulmonary Fibrosis Treatment Market - Global Market Analysis

6.1 Idiopathic Pulmonary Fibrosis Treatment - Global Market Overview
6.2 Idiopathic Pulmonary Fibrosis Treatment - Global Market and Forecast to 2030

7. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By Drug Type, 2020-2030

7.1 Overview
7.2 Nintedanib
7.3 Pirfenidone
7.4 Others

8. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million) - By End User, 2020-2030

8.1 Overview
8.2 Hospitals Pharmacies
8.3 Retail Pharmacies
8.4 Online Pharmacies

9. Idiopathic Pulmonary Fibrosis Treatment Market - Revenue Analysis (USD Million), 2020-2030 - Geographical Analysis

9.1 North America
- 9.1.1 North America Idiopathic Pulmonary Fibrosis Treatment Market Overview
- 9.1.2 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts to 2030
- 9.1.3 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Drug Type
- 9.1.4 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By End User
- 9.1.5 North America Idiopathic Pulmonary Fibrosis Treatment Market Revenue and Forecasts and Analysis - By Countries
  - 9.1.5.1 United States Idiopathic Pulmonary Fibrosis Treatment Market
    - 9.1.5.1.1 United States Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
    - 9.1.5.1.2 United States Idiopathic Pulmonary Fibrosis Treatment Market, by End User
  - 9.1.5.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market
    - 9.1.5.2.1 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
    - 9.1.5.2.2 Canada Idiopathic Pulmonary Fibrosis Treatment Market, by End User
  - 9.1.5.3 Mexico Idiopathic Pulmonary Fibrosis Treatment Market
    - 9.1.5.3.1 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by Drug Type
    - 9.1.5.3.2 Mexico Idiopathic Pulmonary Fibrosis Treatment Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

9.2 Europe
- 9.2.1 Germany
- 9.2.2 France
- 9.2.3 Italy
- 9.2.4 Spain
- 9.2.5 United Kingdom
- 9.2.6 Rest of Europe
9.3 Asia-Pacific
- 9.3.1 Australia
- 9.3.2 China
- 9.3.3 India
- 9.3.4 Japan
- 9.3.5 South Korea
- 9.3.6 Rest of Asia-Pacific
9.4 Middle East and Africa
- 9.4.1 South Africa
- 9.4.2 Saudi Arabia
- 9.4.3 U.A.E
- 9.4.4 Rest of Middle East and Africa
9.5 South and Central America
- 9.5.1 Brazil
- 9.5.2 Argentina
- 9.5.3 Rest of South and Central America

10. Industry Landscape

10.1 Mergers and Acquisitions
10.2 Agreements, Collaborations, Joint Ventures
10.3 New Product Launches
10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

11.1 Heat Map Analysis by Key Players
11.2 Company Positioning and Concentration

12. Idiopathic Pulmonary Fibrosis Treatment Market - Key Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies